Business
DiaMedica Therapeutics Announces Poster Presentation at European Stroke Organisation Conference – ESOC 2025
MINNEAPOLIS, May 14, 2025--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for severe ischemic diseases, announced today a poster presentation of the safety and clinical outcomes for ReMEDy2 study, the planned pivotal phase 2/3 trial of DM199 in AIS patients, at the 11th European Stroke Organisation Conference – ESOC 2025 being held in Helsinki, Finland from May 21-23, 2025. For information about the event, visit: http
About this update from Diamedica Therapeutics Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":2000,"height":631,"url":"https://media.zenfs.com/en/business-wire.com/8992a05c75353a2acb0bfcf7697272c5"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/dNPp9XMf_xxgVAvZ6BqwYw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTMwMztjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/8992a05c75353a2acb0bfcf7697272c5","width":960,"height":303},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/u_NGhR1RyfREHNPbH8citQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD03NTg7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/8992a05c75353a2acb0bfcf7697272c5","width":1200,"height":379}},"lazy":false},{"type":"text","content":"MINNEAPOLIS, May 14, 2025--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for severe ischemic diseases, announced today a poster presentation of the safety and clinical outcomes for ReMEDy2 study, the planned pivotal phase 2/3 trial of DM199 in AIS patients, at the 11th European Stroke Organisation Conference – ESOC 2025 being held in Helsinki, Finland from May 21-23, 2025. For information about the event, visit: https://eso-stroke.org/esoc2025/.","length":546,"tagName":"p"},{"type":"text","content":"The DiaMedica poster is:","length":24,"tagName":"p"},{"type":"table","headerItems":[],"items":[{"val":[{"colspan":"1","rowspan":"1","style":"vertical-align:top;padding-left:0.0px;text-align:left;width:20%;","val":[{"type":"text","content":"Poster Title:","length":13,"tagName":"p","attribs":{}}]},{"colspan":"1","rowspan":"1","style":"vertical-align:top;padding-left:0.0px;width:2%;","val":[{"type":"text","content":" ","length":6,"tagName":"p","attribs":{}}]},{"colspan":"1","rowspan":"1","style":"vertical-align:top;padding-left:0.0px;text-align:left;width:78%;","val":[{"type":"text","content":""Assessing Safety and Clinical Outcomes of Rinvecalinase Alfa (DM199) in Acute Ischemic Stroke Patients Pre-treated with Intravenous Thrombolytics Only"","length":162,"tagName":"p","attribs":{}}]}]}],"length":181},{"type":"text","content":"The poster is P-704. On Thursday May 22, 2025, John J. Volpi, MD, ReMEDy2 trial Scientific Advisory Board Member, will be present to answer questions about the poster. Fol...